Polysubstance Use and Related Risk Behaviors among People Who Inject Drugs in Kenya Preparing for Hepatitis C Virus Treatment

• Published in: Viruses Vol. 16; no. 8; p. 1277
• Main Authors: Riback, Lindsey R., Nyakowa, Mercy, Lizcano, John A., Zhang, Chenshu, Cherutich, Peter, Kurth, Ann E., Akiyama, Matthew J.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 10.08.2024; MDPI
• Subjects: Behavior; Cannabis; Drug abuse; Drug use; Flunitrazepam; Harm reduction; Health aspects; Hepatitis C; Hepatitis C virus; Hepatitis C Virus (HCV); Heroin; HIV; Human immunodeficiency virus; Infection; Infections; injection drug use (IDU); low- and middle-income country (LMIC); Marijuana; Patient compliance; people who inject drugs (PWID); polysubstance use (PSU); Regression analysis; Sociodemographics; sub-Saharan Africa (SSA); Substance abuse; Variables; Kenya; Bangladesh
• ISSN: 1999-4915; 1999-4915
• DOI: 10.3390/v16081277

Polysubstance use (PSU), injection drug use (IDU), and equipment sharing are associated with bloodborne infection (BBI) transmission risk, particularly Hepatitis C Virus (HCV), yet data on PSU in low- and middle-income countries (LMICs) is limited. We report on baseline PSU, medication-assisted treatment (MAT) engagement, and motivation to reduce IDU among 95 people who inject drugs (PWID) who accessed needle and syringe programs (NSP) in Nairobi and Coastal Kenya prior to HCV treatment. Bivariate and multivariate logistic regression were used to examine the associations between PSU and behaviors that confer HCV transmission and acquisition risks. Most participants (70.5%) reported PSU in the last 30 days, and one-third (35.8%) reported PSU exclusive to just heroin and cannabis use. Common combinations were heroin and cannabis (49.3%), and heroin, cannabis, and bugizi (flunitrazepam) (29.9%). Participants at baseline were receiving MAT (69.5%), already stopped or reduced IDU (30.5%), and were HIV-positive (40%). PSU was significantly associated with IDU (p = 0.008) and the number of times (p = 0.016) and days (p = 0.007) injected in the last 30 days. Participants reported high PSU and equipment sharing, despite high MAT engagement. While co-locating BBI treatment within existing harm reduction services is necessary to promote uptake and curb re-infection, tailored services may be needed to address PSU, particularly in LMICs.